![]() ![]() How so? A price of about $2 million would be reasonable for treatment with exa-cel.Īnd together with its partner, CRISPR Therapeutics, Vertex plans to target 32,000 SCD and TDT patients initially. This gene-editing therapy for sickle cell disease (SCD) and beta-thalassemia (TDT) could easily be worth an initial $64 billion. Even assuming it reasonably reflects the growth of Vertex's CF franchise, the company has a massive potential approval on the way, namely that of exa-cel. The estimate of 8.2% growth per year also seems highly conservative, at least to me. That's pretty good for a biotech giant, but it's well below Vertex's nearly 38% annual top-line growth in the past five years. Analysts see the company's top line increasing by 8.2% per year in the next five years. Vertex Pharmaceuticals has several other potential CF approvals that could land well before 2028, but even excluding those, its CF-related revenue in the next half-decade should grow at a good pace. Recently, Vertex's Kalydeco earned approval to treat infants with CF as young as one month old, something that could be meaningful over the mid-term in growing its revenue. ![]() Its most important product is Trikafta, which can treat up to 90% of CF patients (more than 20,000 out of 88,000 of whom are untreated). It's the only drugmaker that sells medicines targeting the underlying causes of CF. But even without exact numbers, we can get a feel for Vertex's revenue and earnings prospects across the next five years.Ĭonsider the company's cystic fibrosis (CF) franchise. That can be difficult given the sheer number of unknowns. Looking at its prospectsĬalculating a company's forward P/S and P/E multiples requires estimating future sales and earnings. To read this article on click here.VRTX PE ratio (forward), data by YCharts. ![]() Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Investors should take the time to consider JAZZ for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. JAZZ has an average earnings surprise of 12.8%. The Zacks Consensus Estimate has increased $0.57 to $17.05 per share. 11 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. Shares of Jazz Pharmaceuticals are trading at a forward earnings multiple of 8.8X, as well as a PEG Ratio of 1.1, a Price/Cash Flow ratio of 6.5X, and a Price/Sales ratio of 2.8X. JAZZ boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Xywav was also approved for treating idiopathic hypersomnia (IH). Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. ![]() Why Investors Should Pay Attention to This Value Stockĭifferent than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |